重组人肝再生增强因子可逆转免疫损伤性肝纤维化

The reversal effects of recombinant human augmenter of liver regeneration to immunocomplex induced liver fibrosis

目的：了解重组人肝再生增强因子（ｈＡＬＲ）抗免疫损伤性肝纤维化的活性。方法：建立人血白蛋白免疫损伤性大鼠肝纤维化模型。模型完成后予ｈＡＬＲ腹腔注射。观察肝纤维化大鼠血清丙氨酸转氨酶（ＡＬＴ）、天冬氨酸转氨酶（ＡＳＴ）、乳酸脱氢酶（ＬＤＨ）水平，肝组织胶原蛋白含量及肝脏病理学改变。结果：重组人肝再生增强因子（ｈＡＬＲ）可降低肝纤维化大鼠的ＡＬＴ、ＡＳＴ、ＬＤＨ水平；肝组织胶原蛋白含量的测定表明ｈＡＬＲ治疗组大鼠肝组织胶原含量明显低于模型组及阴性对照组；病理组织切片也发现ｈＡＬＲ治疗组大鼠肝纤维化程度较模型组及阴性对照组明显减轻。结论：重组人肝再生增强因子（ｈＡＬＲ）可逆转免疫损伤性大鼠肝纤维化。

To observe the anti-fibrosis activity of recombinant human augmenter of liver regeneration (hALR). METHODS: Albumin induced rat model of liver fibrosis was established and hALR was given peritoneally after the model production. Serum concentration of alanine aminotransferase(ALT), aspartic aminotransferase(AST), lactate dehydrogenase(LDH), hepatic collagen contents and pathological examination were selected as observing parameter. RESULTS: Recombinant human augmenter of liver regeneration (hALR) could decrease ALT, AST, LDH concentration of fibrotic rats. The measurements of hepatic collagen contents showed that hepatic collagen contents in hALR treatment group was much lower than those of model group and negative control group. Pathological examination also indicated that the degree of liver fibrosis in hALR treatment group was attenuated in comparison with those of model group and negative control group. CONCLUSION: Recombinant human augmenter of liver regeneration (hALR) had reversal effects on immunocomplex induced rat liver fibrosis.